汉氏联合品牌怎么样 申请店铺

我要投票 汉氏联合在干细胞行业中的票数:205 更新时间:2025-04-26
汉氏联合是哪个国家的品牌?「汉氏联合」是 北京汉氏联合生物技术股份有限公司 旗下著名品牌。该品牌发源于北京,由创始人韩忠朝在2007-01-08期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力汉氏联合品牌出海!通过在本页面挂载汉氏联合品牌的产品链接和联系方式,可以提高汉氏联合产品曝光!跨境电商爆单神器,目前只要100元/年哦~

汉氏联合怎么样

北京汉氏联合生物技术股份有限公司(简称“汉氏联合”)成立于2007年,是国家认定的高新技术企业。作为干细胞产业领域的先锋企业,汉氏联合致力于人类生命健康发展,以干细胞再生医学技术为核心,逐步形成以围产期干细胞存储、细胞及再生医学技术开发、药物研发为主导的科技平台,以精准再生医学、健康管理、医院集团、教育培训、生物护肤及国际医疗旅游为主导的医疗健康平台,旨在打造干细胞再生医学全产业链闭环。

目前,汉氏联合已在全国发展布局19家子公司,2015年,集团在法国建立了首家海外子公司-法国汉氏联合(H&B France),成功跻身国际市场。汉氏联合集团聚集了一批国家级乃至国际级专家和科技人员,科研团队凭借强大的研发实力,自主研发几十项专利技术并多次创造行业记录,研究成果荣获国家科技进步一等奖和二等奖各1项、10余项省部级科技进步一等奖和二等奖。

自90年代至今,以董事长韩忠朝院士为代表的科研团队成功倡导三次围产期干细胞技术革命,成为国内甚至全球范围内围产期干细胞技术研发的风向标。汉氏联合集团在中国开创了同时可以保存多种胎盘组织源干细胞的干细胞银行,截至2019年,汉氏联合按各省市要求在北京、天津、山东、广东、福建、江西与贵州建设7家干细胞库。

一直以来,汉氏联合都专注于干细胞新药研发领域。2011年,汉氏联合集团在全球范围内率先发明以基于胎盘间充质干细胞移植治疗II型糖尿病技术,还开展了胎盘组织来源的造血干细胞的临床转化。基于汉氏联合的研发技术,共自主研发了10余款干细胞新药。2019年,集团自主研发的1类新药“人胎盘间充质干细胞凝胶”获得国家食品药品监督管理总局(NMPA)临床试验默示许可,这是全球第一款以活的胎盘间充质干细胞与生物材料混合制备的皮肤外用药物。此外,汉氏联合研发的注射用生物制品“注射用间充质干细胞(脐带)”新药也获NMPA受理;“高活性间充质干细胞注射液” I/IIa期于2019年获得法国药监局(ANSM)临床试验许可。

在精准再生医学领域,公司致力于干细胞再生医学、肿瘤细胞分型、遗传筛查、免疫细胞治疗、循环肿瘤细胞(CTC)和循环肿瘤DNA(ctDNA)等精准医学和临床转化医学的研究。汉氏联合借鉴美国梅奥医疗中心的经验,正在打造以医疗服务为中心的汉氏联合医学平台,包括生命科学院(本科院校)、三级医院、综合门诊部、体检中心、临检中心及互联网+医院。

汉氏联合集团以“干细胞再生医学技术产品”、“干细胞技术服务”以及“精准医疗服务”三大业务为核心板块,采用科学的资源整合、先进的运营模式、“以人为本”的价值理念,打造民族品牌的“产、学、研、医、养、美”联合体,引领再生医学产业,为人民提供优质的医疗健康服务。


Founded in 2007, Beijing Hanshi United Biotechnology Co., Ltd. (hereinafter referred to as "Hanshi united") is a high-tech enterprise recognized by the state. As a pioneer in the field of stem cell industry, Hans United is committed to the healthy development of human life. With stem cell regenerative medicine technology as the core, it has gradually formed a technology platform dominated by perinatal stem cell storage, cell and regenerative medicine technology development, and drug research and development, with precision regenerative medicine, health management, hospital group, education and training, biological skin care and international medical treatment Tourism as the leading medical and health platform aims to create a closed-loop of the whole industry chain of stem cell regenerative medicine. At present, Heinz Union has developed 19 subsidiaries in China. In 2015, the group established the first overseas subsidiary in France, H & bfrance, and successfully entered the international market. Hanshi United Group has gathered a group of national and even international experts and scientific and technological personnel. With strong R & D strength, the scientific research team independently researched and developed dozens of patented technologies and created industry records for many times. The research results have won the first and second prizes of national science and technology progress, respectively, and more than 10 provincial and ministerial science and technology progress first and second prizes. Since the 1990s, the research team, represented by academician Han Zhongchao, chairman of the board of directors, has successfully advocated three revolutions of perinatal stem cell technology, becoming the wind vane of research and development of perinatal stem cell technology at home and even around the world. Han's joint group has created a stem cell bank in China that can simultaneously store a variety of placenta derived stem cells. By 2019, Han's joint group has built seven stem cell banks in Beijing, Tianjin, Shandong, Guangdong, Fujian, Jiangxi and Guizhou according to the requirements of various provinces and cities. For a long time, Hamilton Union has been focusing on the research and development of new stem cell drugs. In 2011, Hans group took the lead in the world in inventing the technology of treating type II diabetes mellitus based on placental mesenchymal stem cell transplantation, and also carried out the clinical transformation of placental tissue-derived hematopoietic stem cells. Based on the joint research and development technology of Hans, more than 10 new stem cell drugs have been independently developed. In 2019, the group's 1 new drugs, "human placental mesenchymal stem cell gel", were granted the permission of the national food and Drug Administration (NMPA) clinical trial. This is the world's first skin topical drug produced by the combination of living placenta derived mesenchymal stem cells and biomaterials. In addition, the new drug "mesenchymal stem cells for injection (umbilical cord)" jointly developed by Hans has also been accepted by nmpa; the phase I / IIA of "highly active mesenchymal stem cells injection" has obtained the clinical trial license of ansm in 2019. In the field of precision regenerative medicine, the company is committed to stem cell regenerative medicine, tumor cell typing, genetic screening, immune cell therapy, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) and other precision medicine and clinical transformation medicine research. Han's experience from the Mayo Medical Center in the United States is building a medical center for the Han's joint medical platform, including the Life Sciences Academy (undergraduate), three level hospital, comprehensive outpatient department, physical examination center, clinical examination center and Internet plus hospital. Hanshi united group takes "stem cell regenerative medical technology products", "stem cell technology services" and "precision medical services" as its core businesses, adopts scientific resource integration, advanced operation mode and "people-oriented" value concept to build a national brand "production, learning, research, medicine, nutrition and beauty" consortium, leading the regenerative medical industry and serving the people Provide quality medical and health services.

本文链接: https://brand.waitui.com/c5adab6e2.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

埃隆·马斯克旗下XAI公司正与投资者洽谈 计划融资约200亿美元

埃隆·马斯克旗下的xAI正与投资者洽谈,为其人工智能初创公司及社交媒体业务筹集约200亿美元资金。该笔交易将使公司估值超过1200亿美元,所得资金或可用于偿还马斯克将推特私有化所产生的债务。此轮融资预计将在未来几个月内完成,且有可能筹集到超过200亿美元的资金。数据提供商PitchBook的数据显示,若此笔交易达成,将成为有史以来规模第二大的初创企业融资轮次,仅次于今年早些时候OpenAI获得的400亿美元融资。(财联社)

17分钟前

中国重汽与丰田汽车签署战略合作协议

中国重汽与丰田汽车25日在日本名古屋丰田总部签署战略合作协议。双方联合开发的氢燃料电池牵引车已批量交付市场应用。未来,双方将在氢燃料商用车合作研发、示范运营、推广应用、商业模式创新等领域建立更广泛的合作。(财联社)

17分钟前

中国人民银行行长潘功胜会见新兴市场经济体央行主要负责人

2025年4月国际货币基金组织/世界银行春季会议期间,中国人民银行行长潘功胜在美国华盛顿会见了韩国央行行长李昌镛、巴西央行行长加利波罗、南非央行行长康亚戈、阿根廷央行行长鲍希利,主要就全球经济金融形势、深化双边务实合作等议题交换了意见。 中方强调,当前全球经济复苏充满不确定性,新兴市场和发展中国家应利用日益增强的政治互信和经济互补,通过多边、双边渠道加强政策协调,推进金融务实合作,维护以多边规则为基础的全球治理秩序。(界面)

17分钟前

习近平在中共中央政治局第二十次集体学习时强调,坚持自立自强,突出应用导向,推动人工智能健康有序发展

中共中央政治局4月25日下午就加强人工智能发展和监管进行第二十次集体学习。中共中央总书记习近平在主持学习时强调,面对新一代人工智能技术快速演进的新形势,要充分发挥新型举国体制优势,坚持自立自强,突出应用导向,推动我国人工智能朝着有益、安全、公平方向健康有序发展。(新华社)

17分钟前

上海经信委:将推动整车企业转型,加强智能驾驶大模型等创新应用

“智链未来 共赢新章”2025年长三角新能源汽车产业链供应链创新合作大会于4月25日在国家会展中心(上海)召开。上海市经信委二级巡视员、汽车产业处处长韩大东在会上致辞时表示,汽车产业是上海的重点产业之一。在当前全球汽车产业变革调整窗口期、机遇期,上海全力破解汽车产业转型升级的痛点、堵点,加快打造世界级汽车产业中心,推动长三角一体化发展,近年来取得了一定成效。 韩大东强调,当前,全球汽车竞争格局向电动化、智能化、AI化发展,零部件一体化、集成化、轻量化趋势明显。叠加国际贸易摩擦、关税壁垒等地缘政治影响,汽车产业链面临重塑与变革。为加快提升长三角地区汽车产业全链条竞争力,上海将推动整车企业改革转型,加强智能驾驶大模型等创新技术应用,加快智己、奥迪、尚界等新车型投产上市,促进长三角地区及全国汽车产业链上下游协同发展。(澎湃新闻)

17分钟前

本页详细列出关于汉氏联合的品牌信息,含品牌所属公司介绍,汉氏联合所处行业的品牌地位及优势。
咨询